Dirce Maria Carraro holds a PhD in Biochemistry and Molecular Biology from the Institute of Chemistry, University of São Paulo (1998). During her career, she actively participated in genome projects such as the Xylella fastidiosa Project and the Human Cancer Genome Project, in addition to others developed in Brazil. She is currently the head of the Clinical and Functional Genomics group and responsible for the Research and Development Division of Genomic Diagnosis Center at the A.C.Camargo Cancer Center (ACCCC). She is a member of the board, as well as a teacher and advisor, of the graduate course at Fundação Antônio Prudente/ACCCC. She is dedicated to study Cancer Genetics and Genomics with a focus on transferring new applications of genomics in oncological exams essential for personalized treatment. Develops translational projects aimed at relevant clinical questions in the context of hereditary and sporadic cancer. It has developed projects using liquid biopsy, more specifically in the detection of tumor DNA in body fluids, as a tool to monitor response to treatment, investigate genetic mechanisms of resistance acquired during treatment, and support clinical decision-making.She was awarded the São Paulo Scientific and Technological Merit Award for her contribution to the Xylella fastidiosa Genome Project and the IV Octavio Frias de Oliveira Award for her scientific work (PMID: 24909261) in the Oncology Research modality (2015). She has more than 180 scientific publications to date produced throughout her career. (Source: Lattes Curriculum)
| News published in Agência FAPESP Newsletter about the researcher |
| More itemsLess items |
| TITULO |
| Articles published in other media outlets ( ): |
| More itemsLess items |
| VEICULO: TITULO (DATA) |
| VEICULO: TITULO (DATA) |
The development of ICIs was due to better knowledge of the mechanisms of interaction between the tumor and cells of the immune system, representing a radical change and bringing substantial advances in the field of immuno-oncology. ICIs, such as anti-CTLA4 and anti-PD1, which enhance antitumor immune responses, have significantly altered the natural trajectory of several cancer types in a…
Functional precision oncology is a very young area of medicine, whose main goal is to use patient derived cells as models for predicting response to therapy. These models can be characterized genetically, through gene expression profile and activation of biological pathways. With this information, cells can be challenged with different drug regimens to provide personalized and immediately…
Immune based therapeutics such as checkpoint inhibitors have proven to work across several cancer types and the potential impact novel immuno-oncology targets can have on inducing anti-cancer responses, either as standalone, or as combination/adjuvant therapies is great. Thus, our central overriding scientific focus is to discover and validate immunoregulatory targets with the potential t…
DNA repair provides a major protection against cancer, and germline DNA repair defects in inherited syndromes confer a significant cancer predisposition. It has been shown that biallelic MUTYH mutations are associated with high increased risk of colorectal adenomas and cancer (CRC) compared with the general population, commonly known as MUTYH-associated polyposis (MAP). Moreover, bialleli…
INCiTO-INOTE will continue to support the scientific program previously created by the INCiTO, exploring bench-to-bedside-to-bench concepts, in order to face the challenges that are still limiting cancer prevention, diagnosis and treatment. The Institute will explore its large experience in genetics, epigenetics “comics”, bioinformatics and biomarkers to focus in areas where it can be wor…
This proposal encompasses the molecular aspects involved in risk, development and progression of breast cancer using next generation sequencing as the main approach. Mutation in the susceptibility genes, BRCA1/BRCA2, is one of the most important risk factors of developing breast cancer. The identification of the genetic cause that leads to higher risk of developing breast cancer is cruci…
(Only some records are available in English at this moment)
Immunotherapeutic drugs, such as immune checkpoint inhibitors (ICIs), have revolutionized cancer treatment, significantly increasing patient survival. These drugs stimulate defense cells to fight the tumor and can promote long-lasting effects, possibly by inducing immunological memory in patients (Rui et al., 2023). However, many aspects are still unknown and represent challenges for the …
Breast cancer (BC) is the most common malignant neoplasm in women. Triple-negative (TN)breast cancer subtype is characterized by the absence of expression of estrogen receptor (ER), progesterone (PR) and human epidermal growth factor receptor 2 (HER2). This subtype represents less than 15% of all cases of BC with a higher incidence in young women of African descent (in American women) and…
Triple-negative breast câncer (TNBC), characterizad by lack of significant expression of the estrogen receptor (ER), progesterone receptor (PR) and human epidermal growth factor receptor 2 (HER2), is a most aggressive subtype of breast cancer with poor prognosis and affects approximately 15% of cases of breast cancer. Among the major susceptibility genes for breast cancer are BRCA1 / BRCA…
The elucidation of the mechanisms of cancer pathogenesis involves the identification and analysis of DNA somatic variations. Undoubtly cancer diagnosis and therapy will be improved with the advent of Next Genetation Sequencing technologies (NGS). Thanks to NGS technology it has become feasible to dected several types of genomic variation, e.g, single-nucleotide variations, insertions and…
(Only some records are available in English at this moment)
| 3 / 3 | Ongoing grants |
| 7 / 7 | Completed research grants |
| 2 / 2 | Ongoing scholarships in Brazil |
| 19 / 12 | Completed scholarships in Brazil |
| 31 / 24 | All research grants and scholarships |
| Associated processes | |
CV Lattes
ORCID